Avalo Therapeutics, Inc
Price
FilingsNewest: 13G, Stake over 5%, passiveAug 7 →InsidersNo open-market buys. 5 insiders sold $6.5M, 30 of 32 sales on a 10b5-1 plan.→HoldersFMR 9.6%BlackRock 8.3%Nantahala 7.0%→Financing →PeersClosest companies: KAPA, PRLD, VTGN→
From the filings
Figures
- Revenue
- $59,000last 12 months
- Net income
- −$100.3Mlast 12 months
- Operating cash flow
- −$59.7Mlast 12 months
- Cash and equivalents
- $85.4Mat the last balance sheet
- Shares outstanding
- 52.9M shareson issue